Last edition
News about
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced a new agreement to commercialize the Moderna Covid-19 vaccine across Central Eastern Europe and Israel
Novartis announced results from the pivotal phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001). The study evaluated tislelizumab in patients with unresectable recurrent locally advanced
CSIR and Laxai Life Sciences initiate clinical trials of drug niclosamide for Covid-19 treatment
CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated phase-II clinical trial with anti-helminitic drug niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of niclosamide for the treatment of hospitalized Covid-19 patients.
Lupin receives US FDA approval for generic Truvada tablets
Global pharma major Lupin Limited has received approval for its emtricitabine and tenofovir disoproxil fumarate tablets, 200 mg/300 mg, from the United States Food and Drug Administration (FDA), to market a generic equivalent of Truvada tablets, 200 mg/300 mg, of Gilead Sciences, Inc.
Moderna inks agreement with Government of the Republic of Botswana for supply of Covid-19 vaccine
Moderna announced a supply agreement with the Government of the Republic of Botswana for Moderna's vaccine against Covid-19, to support the government's ongoing efforts to secure access to Covid-19 vaccines for the people of Botswana. The Company also announced that the Botswana Medicines Regulatory Authority (BMRA)
Bayer enters agreement to buy Noria Therapeutics and PSMA Therapeutics
Bayer announced that it has entered into an agreement to acquire Noria Therapeutics (Noria) and PSMA Therapeutics. Through this acquisition, Bayer will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA)
Bharat Biotech signs agreement with Ocugen to commercialise Covaxin in Canada
Ocugen, Inc., a biopharmaceutical company, and Bharat Biotech, a global leader in vaccine innovation, announced that they have entered into an amendment to their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to commercialize Covaxin to now also include Canada
Glenmark Pharma receives US FDA approval for theophylline ER tablets
Glenmark Pharmaceuticals Limited (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for theophylline extended release tablets, 300 mg and 450 mg, bioequivalent and therapeutically equivalent to the reference listed drug, theophylline extended release tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Lmt
Bayer launches consumer health division in India
Bayer, a global life sciences company, now announces the launch of its consumer health division in India. Globally, Bayer's Consumer Health division encompasses over 140 brands. The newly launched consumer health business in India comprises of 10 trusted consumer health brands across the categories of allergy, dermatology, nutrition and analgesics
ACHEMA Pulse: More than 900 exhibitors present their innovations
From 31 May 2021, 940 exhibitors from 37 countries are taking the opportunity to present their products and solutions for the process industry to interested parties worldwide. At the virtual ACHEMA Pulse, they showcase everything from gas detectors to packaging lines, from materials to IT solutions that the chemical, pharmaceutical or food industries
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy